Totally Implanted Access Ports: Indications and Prevention of Complications

  • Didier S. Kamioner


Repeated venipunctures are often aggressive, painful, and sometimes dangerous, especially with the risk of severe extravasation during the administration of anticancer chemotherapy. An implanted central catheter (ICC) can be used for chemotherapy, infusions, transfusions, and blood samples and for the administration of various medications or parenteral nutrition requiring repeated access to the venous system. The installation must be done by a trained operator in surgical aseptic conditions. To prevent complications, training, information, protocols, and evaluation are recommended. Nevertheless, some important complications may occur during installation or use of the device (hematoma, pneumothorax, thrombosis, extravasation, infection, no reflux, etc.).


Totally implanted access ports Venipuncture Thrombosis Catheter infection Extravasation Recall reaction Huber needle Venous reflux Pinch-off syndrome Costoclavicular clamp 


  1. 1.
    Kamioner D, Kriegel I. Abord veineux de longue durée. Référentiels interrégionaux des réseaux de cancérologie. Paris: AFSOS; 2010.Google Scholar
  2. 2.
    Ackermann M, Cosset-Delaigue MF, Kamioner D, Kriegel I. L’abord veineux de longue durée dans le cancer du sein. Dispositifs veineux implantables (DVI): indications, pose et complications. Oncologie. 2009;11(12):621–34.Google Scholar
  3. 3.
    Marcy PY. Central venous access: techniques and indications in oncology. Eur Radiol. 2008;18(10):2333–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Vescia S, Baumgärtner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S, et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol. 2008;19(1):9–15.CrossRefPubMedGoogle Scholar
  5. 5.
    Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol. 2009;20(5):935–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Ackermann M, Cosset-Delaigue MF, Kamioner D, Kriegel I. Extravasation. Oncologie. 2009;11(12):634–41.Google Scholar
  7. 7.
    Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc. 2006;81(9):1159–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Crisinel M, Mahy S, Ortega-Debalon P, Buisson M, Favre JP, Chavanet P, et al. Incidence, prevalence and risk factors for a first infectious complication on a totally implantable venous-access port. Med Mal Infect. 2009;39(4):252–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Saber W, Moua T, Williams EC, Verso M, Agnelli G, Couban S, et al. Risk factors of catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011;9(2):312–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Beckers MM, Ruven HJ, Seldenrijk CA, Prins MH, Biesma DH. Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. Thromb Res. 2010;125(4):318–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol. 2009;20(9):1459–71.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Didier S. Kamioner
    • 1
  1. 1.Department of Medical Oncology and HematologyHôpital Privé Ouest ParisienTrappesFrance

Personalised recommendations